|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term bank deposits | ||||||||||||||||||||
| Restricted deposit | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| NON-CURRENT ASSETS: | ||||||||||||||||||||
| Funds in respect of employee rights upon retirement | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| R&D grant receivable | ||||||||||||||||||||
| Deferred income tax asset | ||||||||||||||||||||
| Operating lease right of use assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable and accruals: | ||||||||||||||||||||
| Trade | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Contracts liability | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| LONG TERM LIABILITIES: | ||||||||||||||||||||
| Liability for employee rights upon retirement | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common Stock, $0.001 par value: Authorized - as of December 31, 2024 and 2025, 185,000,000 shares; issued and outstanding - as of December 31, 2024 and 2025, 75,850,275 and 80,425,981 shares, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
